MagnetisMM
Showing 1 - 14 of 14
Relapsed or Refractory Multiple Myeloma Trial in Nagoya, Shibuya-ku (Elranatamab (PF-06863135))
Active, not recruiting
- Relapsed or Refractory Multiple Myeloma
- Elranatamab (PF-06863135)
-
Nagoya, Aichi, Japan
- +1 more
Jun 20, 2022
Multiple Myeloma Trial in Worldwide (Elranatamab, Daratumumab, Lenalidomide)
Recruiting
- Multiple Myeloma
- Elranatamab
- +3 more
-
Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
- +7 more
Jan 9, 2023
Multiple Myeloma Trial in Worldwide (Elranatamab (PF-06863135))
Active, not recruiting
- Multiple Myeloma
- Elranatamab (PF-06863135)
-
Beverly Hills, California
- +75 more
Oct 4, 2022
Medicine Called Elranatamab in People With Relapsed Refractory
Not yet recruiting
- Multiple Myeloma
- Elranatamab
- Standard of care
- (no location specified)
Jun 30, 2023
Multiple Myeloma Trial in Montréal (Elranatamab)
Not yet recruiting
- Multiple Myeloma
-
Montréal, Quebec, CanadaMcGill University Health Centre
Sep 21, 2023
Multiple Myeloma Trial in Worldwide (Elranatamab, Daratumumab, Pomalidomide)
Recruiting
- Multiple Myeloma
- Elranatamab
- +3 more
-
Woolloongabba, Queensland, Australia
- +117 more
Aug 3, 2022
Multiple Myeloma Trial in Canada, United States (PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 +
Active, not recruiting
- Multiple Myeloma
- PF-06863135 monotherapy IV or SC
- +3 more
-
Encinitas, California
- +37 more
Jul 7, 2022
Multiple Myeloma Trial in Beverly Hills (Elranatamab, Carfilzomib)
Recruiting
- Multiple Myeloma
-
Beverly Hills, CaliforniaBeverly Hills Cancer Center
Dec 21, 2022
Multiple Myeloma Trial (Elranatamab (PF-06863135))
Temporarily not available
- Multiple Myeloma
- Elranatamab (PF-06863135)
- (no location specified)
Jul 15, 2022
Multiple Myeloma Trial in Worldwide (Elranatamab, Lenalidomide)
Recruiting
- Multiple Myeloma
-
Benowa, Queensland, Australia
- +132 more
Jan 24, 2023